Nebivolol reduces short-term blood pressure variability more potently than irbesartan in patients with intradialytic hypertension.
Loutradis C, Bikos A, Raptis V, Afkou Z, Tzanis G, Pyrgidis N, Panagoutsos S, Pasadakis P, Balaskas E, Zebekakis P, Liakopoulos V, Papagianni A, Parati G, Sarafidis P.
Loutradis C, et al. Among authors: tzanis g.
Hypertens Res. 2019 Jul;42(7):1001-1010. doi: 10.1038/s41440-018-0194-2. Epub 2019 Jan 8.
Hypertens Res. 2019.
PMID: 30622317
Clinical Trial.